90
Participants
Start Date
July 11, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
B013
B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
Paclitaxel
Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.
Placebo
Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Affiliated Hospital of Bengbu Medical University, Bengbu
RECRUITING
XiangYa Hospital CentralSouth University, Changsha
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
RECRUITING
Cancer Hospital of Shandong First Medical University, Jinan
RECRUITING
Qilu Hospital of Shandong University, Jinan
RECRUITING
Yunnan Cancer Hospital, Kunming
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
RECRUITING
Fudan University Shanghai Cancer center, Shanghai
RECRUITING
The Obstetrics & Gynecology Hospital of Fudan University, Shanghai
RECRUITING
The Second Hospital of Hebei Medical University, Shijiazhuang
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Shananxi Provincial Cancer Hospital, Xi'an
RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
Yibin city second people's Hospital, Yibin
RECRUITING
Henan Cancer Hospital, Zhengzhou
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY
Shanghai Jiaolian Drug Research and Development Co., Ltd
INDUSTRY